Safety and Efficacy of a Switch to Doravirine, Tenofovir, Lamivudine (MK-1439A) in Human Immunodeficiency Virus (HIV-1)-Infected Participants Virologically Suppressed on an Anti-retroviral Regimen in Combination with Two Nucleoside Reverse Transcriptase Inhibitors (MK-1439A-024)

Trial Identifier: 1439A-024
Sponsor: MSD
Start Date: June 2015
Primary Completion Date: February 2018
Study Completion Date: September 2023
Condition: Human Immunodeficiency Virus (HIV)

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
Results Plain Language Summary – NA French Canadian
Results Plain Language Summary – EMEA French (Belgium)
Results Plain Language Summary – EMEA Spanish
Results Plain Language Summary – EMEA German
Results Plain Language Summary – EMEA German
Results Plain Language Summary – EMEA Italian
Results Plain Language Summary – English
Results Plain Language Summary – EMEA Dutch (Belgium)
Results Plain Language Summary – EMEA Russian
Results Plain Language Summary – EMEA Danish
Results Plain Language Summary – EMEA French
Results Plain Language Summary – LA Spanish
Results Plain Language Summary – EMEA Polish
Results Plain Language Summary – EMEA German (Belgium)

Trial Locations

No locations posted.